The Science Behind Imatinib: How It Targets Cancer Cells 

Cancer is a complex and devastating disease that affects millions of people worldwide. Fortunately, medical advancements have led to the development of targeted therapies such as imatinib that specifically target cancer cells while sparing healthy ones. Imatinib has been hailed as a miracle drug for certain types of cancer, but how does it work at the molecular level? And what are its potential side effects? In this article, we delve into the science behind imatinib and explore its mechanism of action as well as its impact on patients' lives.

Imatinib and Cancer

Imatinib, also known by its brand name Gleevec, is a tyrosine kinase inhibitor that has been used to treat certain types of cancer since 2001. The drug was initially approved for the treatment of chronic myeloid leukemia (CML), a type of blood cancer caused by the abnormal growth and proliferation of white blood cells in bone marrow.

Imatinib works by targeting specific proteins called tyrosine kinases that are present on the surface of cancer cells. These kinases play an important role in promoting cell growth and division, which is why they are often overactive in tumor cells. By blocking these proteins, imatinib can slow down or even halt cancer cell growth.

In addition to CML, imatinib has also been used to treat other types of cancers such as gastrointestinal stromal tumors (GISTs) and dermatofibrosarcoma protuberans (DFSP). In clinical trials, imatinib has shown significant improvements in progression-free survival rates for patients with these conditions.

Conclusion

Druker and his colleagues tested imatinib in a phase 1 clinical trial partially funded by NCI. The drug caused cancer to disappear in the majority of patients with CML that was in the early, or chronic, phase of the disease. Five years later, 98% of patients from this trial were still in remission.